Perspective on key issues
Novartis believes transparency and partnership are key drivers toward finding long-term, sustainable solutions to global health challenges.
To this end, Novartis maintains relationships with key public health stakeholders including government officials, politicians, regulatory authorities, international organizations, nongovernmental organizations and patient groups. We engage in major policy debates, sharing the company’s perspective on public health issues and striving for open and constructive interaction.
As part of our ongoing commitment to transparency, we state our position on various issues affecting our business. Please feel free to contact Public Affairs at:
Download the fact sheets:
Access to medicines in the developing world
(89 KB)
Animal experimentation
(72 KB)
Biodiversity/Bioprospecting
(81 KB)
Competitive off-patent markets
(76 KB)
Counterfeit medicines
(80 KB)
Disclosure of clinical research information
(54 KB)
Ethical promotion of pharmaceuticals
(32 KB)
Harmonization of HTA methodology and processes
(76 KB)
Harmonization of Regulatory Requirements for Biosimilar Development
(470 KB)
Health Technology Assessment
(172 KB)
Human rights
(62 KB)
Information to patients
(69 KB)
Interchangeability of Biosimilars
(503 KB)
Naming requirements for Biosimilars
(89 KB)
Nanotechnology-based medicine
(92 KB)
Organ donation
(83 KB)
Patient group interaction and support
(74 KB)
Pharmacovigilance for Biosimilars (Post-marketing surveillance)
(462 KB)
Pharmaceuticals in the environment
(56 KB)
Pricing of Biosimilars
(455 KB)
The Right to Health
(231 KB)